Production (Stage)
Fulcrum Therapeutics, Inc.
FULC
$6.85
$0.071.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.66M | -16.57M | -21.70M | 55.41M | -26.87M |
| Total Depreciation and Amortization | 353.00K | 369.00K | 369.00K | 376.00K | 479.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.27M | 1.53M | 2.67M | 3.21M | 2.76M |
| Change in Net Operating Assets | -223.00K | -2.09M | -410.00K | -96.00K | -1.65M |
| Cash from Operations | -15.26M | -16.76M | -19.07M | 58.90M | -25.28M |
| Capital Expenditure | -- | -231.00K | -19.00K | 0.00 | -28.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -777.00K | 2.49M | 4.37M | -12.51M | 38.16M |
| Cash from Investing | -777.00K | 2.26M | 4.35M | -12.51M | 38.13M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 83.00K | 635.00K | 377.00K | 1.65M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 83.00K | 635.00K | 377.00K | 1.65M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.03M | -14.42M | -14.09M | 46.77M | 14.50M |